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Abstract
Background: Prior evidence shows that behaviours closely related to the intervention delivered for autism
are amenable to change, but it is more difficult to generalise treatment effects beyond the intervention
context. We test an early autism intervention designed to promote generalisation of therapy-acquired skills
into home and school contexts to improve adaptive function and reduce symptoms. A detailed mechanism
study will address the process of such generalisation. Objective 1 will be to test if the PACT-G intervention improves
autism symptom outcome in the home and school context of the intervention as well as in the primary outcome
research setting. Objective 2 will use the mechanism analysis to test for evidence of acquired skills from intervention
generalizing across contexts and producing additive effects on primary outcome.
Methods/design: This is a three-site, two-parallel-group, randomised controlled trial of the experimental treatment
plus treatment as usual (TAU) versus TAU alone. Children aged 2–11 years (n = 244 (122 intervention/122 TAU; ~ 82/
site) meeting criteria for core autism will be eligible. The experimental intervention builds on a clinic-based Pre-
school Autism Communication Treatment model (PACT), delivered with the primary caregiver, combined with
additional theory- and evidence-based strategies designed to enhance the generalisation of effects into naturalistic
home and education contexts. The control intervention will be TAU.
Primary outcome: autism symptom outcome, researcher-assessed using a standardised protocol. Secondary outcomes:
autism symptoms, child interaction with parent or teacher, language and reported functional outcomes in home and
school settings. Outcomes measured at baseline and 12-month endpoint in all settings with interim interaction
measurements (7 months) to test treatment effect mechanisms.
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Primary analysis will estimate between-group difference in primary outcome using analysis of covariance with test of
homogeneity of effect across age group. Mechanism analysis will use regression models to test for mediation on
primary outcome by parent-child and teaching staff-child social interaction.
Discussion: This is an efficacy and mechanism trial of generalising evidence-based autism treatment into home and
school settings. It will provide data on whether extending treatment across naturalistic contexts enhances overall effect
and data on the mechanism in autism development of the generalisation of acquired developmental skills across
contexts.
Trial registration: ISRCTN, ID: 25378536. Prospectively registered on 9 March 2016:
Keywords: Autism spectrum disorder, Randomised trial, Social communication intervention, School-based intervention
Background
Introduction
Intervention research in autism spectrum disorder (ASD)
(hereafter ‘autism’) has recently accelerated, with studies
across a range of interventions considered in recent NICE
guidance [1], Cochrane [2] and other reviews [3–5]. The
pattern of findings across a number of interventions is for
reproducible moderate to good effects on targeted prox-
imal outcomes such as improvement in interaction and
communication in the treatment context [6, 7] but there is
much less evidence for generalisation of treatment effect to
broader symptom change and functional outcome [3]. This
problem of generalising from ‘proximal’ intervention ef-
fects to wider symptom and functional change is a key
current challenge for autism treatment research [4, 8]. The
capacity to generalise acquired skills flexibly across con-
texts is a central feature of successful developmental learn-
ing, and is a major problem for individuals with autism [9].
Parent-mediated and education staff-mediated learning,
providing the same dyadic cues for the child across
different contexts, is one plausible approach to helping
overcome these generalisation difficulties in autism
[10]. Naturalistic learning, in which the learning takes
place within the functional context in which the skills
are actually needed, provides another potential ap-
proach. Working with children in their natural envi-
ronments is now often highlighted as best practice for
early intervention [11].
Early social communication intervention, delivered
through parents, therapists or teachers, is the only autism
treatment currently recommended for consideration by
NICE [1]. The Pre-school Autism Communication Trial
(PACT) tested a clinic-delivered, parent-mediated social
communication intervention against regular care in one of
the largest randomised controlled trials (RCTs) yet in
the field [12]. The therapy showed a substantial im-
pact on the targeted immediate outcome of parental
communicative synchrony with the child (ES 1.22
(95% CI 0.85, 1.59) and also on the child’s communi-
cation initiations with the parent (ES 0.41 (0.08, 0.74).
Autism symptoms spanning social communication and
restricted and repetitive behaviours (measured with a
different interaction partner in a different structured
context) were significantly reduced at treatment end-
point (ES 0·64, 95% CI 0·07, 1·20) and at 6-year
follow-up (ES 0·70, 95% CI − 0·05, 1·47), resulting in a
significant overall effect over the treatment and follow-up
period (ES 0·55, 95% CI 0·14, 0·91). Non-blind parent-
rated autism symptoms on the Social Communication
Questionnaire (ES 0·40, 95% CI 0·05, 0·77) and repetitive
behaviours on the Repetitive Behaviour Questionnaire (ES
0·87, 95% CI 0·47, 1·35) also showed comparable improve-
ment at follow-up [12].
The current Paediatric Autism Communication
Therapy-Generalised (PACT-G) trial now builds on
this clinic-based work by using additional strategies
that are designed to improve generalisation of the ef-
fects demonstrated into wider symptom change and
functional impact in other environments. It does this
by incorporating parent- and education staff-mediated
intervention strategies within the naturalistic learning
contexts of home and school/nursery. A further
development is to extend the application of the inter-
vention into the primary school years. Autism inter-
vention studies to date have been largely limited to
episodic interventions, usually in pre-school. However,
communication skills continue to emerge and develop
beyond the pre-school years [13] and social communi-
cation skills in the early-school-age period are strong
predictors for later development [14]. The persisting
and significant impairments in social interaction and
communication among children with autism argue
strongly for a developmentally sustained approach to
intervention into middle childhood in affected children.
Additionally, a mechanism study within the PACT-G trial
will build on the understanding gained from the
design and mediation analysis in the original PACT
trial [15] by assessing the mediators and outcomes in
the different generalisation contexts, and thus pro-
vides a unique and innovative opportunity to further
understand the processes and facilitation of symptom
change in autism.
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Methods/design
Aims
The PACT-G study has two aims. Firstly, it will test
whether the extended PACT-G social communication
intervention protocol, using targeted enhancement strat-
egies within home and education settings, improves
transmission of treatment effect to:
(1) Researcher-assessed autism symptom outcome; (2)
Autism symptoms and functional adaptation in home
and education settings. This objective will be tested
using blinded measures maximising the ability to detect
meaningful change (see ‘Measures’ below) and evaluated
by analysis at trial endpoint.
The second aim is a mechanism analysis that will use
the experimental trial to illuminate core processes of
generalisation of specific acquired competencies in aut-
ism across context: (1) We will build on the mediation
analysis from our previous PACT Trial (see above) to
test mediation of the generalised treatment effect in
home and school, (2) We will test how effects in natural-
istic contexts may combine to enhance transmission of
effect to research-assessed symptoms in a standardised
test setting. In doing this, we will use the pre-specified
measures of mediation which were successful in our
previous MRC PACT trial.
Design
A three-site, two-group, randomised controlled trial of
the experimental treatment plus TAU compared to TAU
alone. Children aged 2–11 years with core autism will be
recruited to the trial in the local areas following referral
via clinical specialists, education professionals and con-
sented databases. After consent families will be rando-
mised in three sites around the UK to receive either the
PACT-G social communication intervention in addition
to TAU or TAU alone. Assessments are administered on
entry (baseline) to the trial, at the 7-month midpoint
and at the 12-month endpoint. There will be an embed-
ded mechanism study to test mediation hypotheses and
illuminate the basic science underpinning the under-
standing of generalisation impairments in autism.
Settings
NHS clinics, homes, local schools with specialist autism
units, and specialist autism school settings; in Greater
Manchester, London and North-East England.
Study population
Inclusion criteria
 Age 2–11 years
 Diagnosis of autism spectrum disorder (ASD)
 Meeting criteria for autism on the Autism
Diagnostic Observation Schedule-2nd Edition
(ADOS-2) [16] and scoring ≥ 15 (school-aged)
and ≥ 12 (pre-school) on the Social Communication
Questionnaire (SCQ) [17]
 Children who are aged 5 years and over are between
P3 and P8 for the English curriculum [18] (as
reported by relevant professionals; the P levels were
designed to be used for pupils with learning
disability. P3 communication skills indicate that a
child is beginning to use ‘intentional
communication’. P8 represents up to, but not
beyond, a language age equivalent of 4 years in a
typically developing child)
 Parents with sufficient English to potentially
participate in the intervention and who speak
English to their child at least some of the time
Exclusion criteria
 Sibling with autism already in the trial
 Participation in the PACT-G pilot phase
 Children aged ≤ 12 months non-verbal age-
equivalent level
 Epilepsy not controlled by medication
 Severe hearing or visual impairment in parent or
child
 Current severe learning disability in the parent, or
current severe parental psychiatric disorder
 Current safeguarding concerns or other family
situation that would affect child/family participation
in the trial
 No agreement to participate from child’s education
setting
 Children with an identified genetic disorder that
would impact on ability to participate or affect
validity of data; eligibility to be determined by the
principal investigators (PIs) on a case-by-case basis
Treatment principles
PACT-G is an enhancement of the original clinic-based
PACT therapy. This is a ‘carer-mediated’ therapy in which
caregivers are coached, using video-feedback, to interact
with the child using evidence-based strategies that facili-
tate social communication development in the child.
Optimal interaction with a sensitive and responsive com-
munication partner (such as the parent/caregiver) increases
communication and social interaction skills in the child. In
the original PACT trial this approach was found to be very
effective in increasing the quality of parental communica-
tive responses to the child, which in turn led to increased
child-initiated social communications with the parent.
PACT-G retains these effective elements but adds new
features to aid the generalisation of the child’s newly ac-
quired skills into other settings, recognising that such gen-
eralisation is a particular problem in autism. PACT-G
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encourages generalisation of skills by extending the ther-
apy into the home and school settings, by integrating the
parental techniques into daily routines and play, and by
widening the range of adults involved in training to in-
clude education staff in addition to parents/carers. The
therapy generally begins with the parent at home then
extends into the educational setting but flexibility in
timing is built in to fit with school terms, with an overlap
to allow for essential supported joint collaboration with
parent and education staff.
PACT-G has also been modified to incorporate recent
advances in research, focussing on specific strategies to
enhance the child’s response to adult-directed shared
attention and to develop object interest and play. These
are important precursors to the early stages of language
development [19, 20] and have been shown to moderate
treatment response in recent social communication early
autism trials [21]. Further modifications allow more in-
dividual differentiation so that intervention begins at a
point appropriate to the child’s initial level of object
interest and social engagement.
PACT-G, in common with the original PACT therapy,
takes a staged approach, which is based on theoretically
informed child developmental progression and strategies
for establishing essential foundation skills such as shared
attention. Parents and education staff are helped to rec-
ognise and facilitate child motivated play and increase
their synchrony and sensitive responding (stages 1–2)
with verbal comments on child action and play. Middle
stages (stages 3–4) of PACT-G develop language compre-
hension and expression through commenting on the
child’s activity, language ‘mapping’ and modelling, and en-
courage child communication initiations through the use
of anticipation and other eliciting techniques. For children
who make the most progress, later stages (stages 5–6)
encourage language expansion and conversation. PACT-G
is appropriate for pre-school and also primary-school-age
children who have lower functioning autism. Some chil-
dren are likely to be at the earliest stages of communi-
cation development, making the early developmental
PACT-G stages focussing on shared attention, adapted
parent/ education staff responding and eliciting child
communication initiation appropriate. Other children
may be verbally fluent making appropriate the later
PACT-G stages, which focus on language understand-
ing, expression, language expansions and conversation.
The sequence of delivery of the PACT-G intervention
is set out visually in Fig. 1.
Parent sessions
Based on what was found to be most effective in the ori-
ginal PACT trial, parents will receive 12 intervention
sessions. Prior to starting the intervention, a home visit
is conducted to introduce the intervention to the par-
ents, explore the family context and set expectations.
The therapy sessions are delivered in the home. Subse-
quent sessions alternate between home-based sessions
and Skype/telephone-delivered consultation. Delivery is
flexible in accordance with the needs of the family. This
approach will assist generalisation of new skills develop-
ment in the home setting. Clinical and research experi-
ence indicates that these session formats are popular
with parents [22]. Each parent session begins with a
discussion of progress made since the last session. The
parent and child are then filmed whilst playing for
10 min. Immediately after this the therapist and parent
watch the film, or during Skype sessions the therapist
and parent watch a 1–2 min parent-made video of a
home-based practice session routine. The therapist facil-
itates the parent to identify actions that lead to child
Fig. 1 Intervention and assessment timeline. Legend: *Start of education element accommodates school terms. Key: BOSCC Brief Observation of
Social Communication Change, ADOS Autism Diagnostic Observation Schedule-2; HSC Home-School Conversation (see text)
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communication and to adopt PACT-G strategies in
their interaction with the child. Parents are assisted
to set goals for themselves, based on the interaction
strategies discussed. The parent and therapist dis-
cuss the opportunities to practice these strategies
each day outside of therapy sessions and parents are
asked to make time to practice them daily for half
an hour.
Education-setting sessions
In most cases, therapy in the educational setting begins
after the parent has commenced therapy at home. The
start times and duration of education-based therapy are
flexible to fit around the school-term schedule. In the edu-
cation setting PACT-G sessions will be delivered to trained
learning support assistants (LSA), who are staff with a spe-
cific remit to assist children with special educational needs
to access the curriculum- and broader school-based activ-
ities, e.g. mealtimes, etc. LSAs and other education staff
receive an initial training session to introduce them to
PACT-G. The education-based intervention then consists
of therapist-LSA sessions that mirror the therapist-parent
sessions in the home. Videos are made of the LSA and the
child and are used to coach the LSA in the use of PACT-G
strategies in a similar procedure to the parent. The LSA
then implements these with the child daily in class time.
There are a maximum of 12 therapist-LSA sessions over
6 months, alternating in-school visits and Skype/telephone
consultation. PACT-G strategies are expected to be inte-
grated in a complementary way with other communication
strategies that may already be in use in the school.
Collaboration between parent and educational staff
Importantly, the separate therapeutic work with parents
and LSAs described above will be supplemented with a
schedule of joint parent-LSA meetings to support the work
and ensure consistent use of strategies across home and
education settings. This is hypothesised as being key to
successful generalisation. The meetings will use the man-
ualised technique of ‘Home-School Conversation’ (HSC).
Meetings are structured around ‘explore’, ‘focus’, ‘plan’ and
‘review’ stages, which allow the LSA and parent to share
experiences and maximize intervention consistency. HSC
is validated and shown to be highly effective in motivating
parents and school staff [23, 24].
Training and fidelity of treatment
Training in the PACT-G will be conducted centrally by
the lead speech and language therapists, who will under-
take overall co-ordination of the therapy in the trial and
will organise quarterly across-site therapist meetings.
Therapists will be regularly supervised by the lead speech
and language therapists in each site. All therapy sessions
will be videotaped and 5% of randomly selected tapes will
be independently rated using the PACT Fidelity Rating
Scale at regular intervals across the trial period. Therapists
in the trial will not be treating any TAU patients. Thera-
pists and research staff will be trained in practices that
minimise non-compliance and drop-out. Therapy compli-
ance and receipt of other interventions outside of the
protocol will be monitored.
Treatment as usual and avoidance of contamination
The control intervention will be treatment as usual (TAU).
We have detailed information on TAU in the pre-school
population from the group’s previous work on the MRC
PACT trial and in older children from the PACT 7–11
follow-up study [25]. Data on services received will be
collected.
There will be separate clinical and research leads
at each site and separate training and supervision
structures. Researchers will be housed separately from
staff involved in delivery of the PACT-G intervention.
Mid- and endpoint research interviews and assessments
will be conducted so as to avoid inadvertent divulging of
information that could infer treatment status. The assess-
ment suite and materials used will be quite different in
type and location to that used for the therapy intervention
in home or education, avoiding any familiarity effect for
children in the treatment arm.
Measures (see Fig. 2)
Primary outcome
Autism Diagnostic Observation Schedule (ADOS-2)
[16, 26] The standard autism diagnostic symptom meas-
ure with good external validity to long-term outcomes in
autism development. Measured within researcher-child
interaction using a standardised set of social presses,
video-recorded for later coding. The scoring metrics of
ADOS have been modified in line with the 2013 DSM-5
[27], with social communication and repetitive behaviour
symptom domains combined into a unitary total symp-
tom score (Social Affect + Restricted and Repetitive Be-
haviour Overall Total raw score). Recent studies [12, 28]
have demonstrated the ability of the ADOS to measure
treatment effects; for instance in the PACT trial [12]
finding effects sustained 6 years after treatment end.
Other measures
Diagnostic inclusion
Mullen Scales of Early Learning [29] or British Abil-
ity Scales [30] Depending on child age and ability level.
Standard measures of non-verbal early development
which enable a developmental level of non-verbal abil-
ities to be ascertained for inclusion criteria and allow
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characterisation of the cohort in relation to other autism
treatment trials.
Social Communication Questionnaire (SCQ) Lifetime
Version [17] A brief (40-item), parent-report screening
measure that identifies characteristics associated with
ASD. Items cover three subdomains: Reciprocal Social
Interaction, Communication, and Restricted, Repetitive
and Stereotyped Patterns of Behaviour. The ‘lifetime’
version of the SCQ refers to the entire developmental
history of the child.
Mechanism testing
Brief Observation of Social Communication Change
(BOSCC) with researcher [31–33] A researcher-coding
Fig. 2 Schedule of assessments. Key: ADOS Autism Diagnostic Observation Schedule-2, MSEL Mullen Scales of Early Learning, BOSCC Brief
Observation of Social Communication Change, DCMA Dyadic Communication Measure for Autism
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of autism symptoms from videotaped child-adult inter-
action. It addresses the same autism symptom construct
as ADOS but is designed to better detect clinically mean-
ingful symptom change in treatment studies, with codes
combining symptom frequency, severity and atypicality on
a 16-item, 0–5 scale (overall range 0–80). The BOSCC is
designed to be a standard treatment outcome measure for
the autism field and is currently used in large funded trials
in the US and the EU. It shows high inter-rater agreement
[31] and increased sensitivity to treatment change com-
pared to ADOS (BOSCC d = 0.64 compared to parallel
ADOS d = 0.42 in a recent 12-month observational inter-
vention study) [34].
Brief Observation of Social Communication Change
(BOSCC) with parent and LSA [31–33] Coded from
video of child-parent play-session in home (baseline,
7-month midpoint, 12-month endpoint) and child-learning
support assistant in school (baseline, 7-month interim,
12-month endpoint); measure of intervention effect in
naturalistic settings in which intervention took place.
Dyadic Communication Measure for Autism (DCMA)
with parent and with LSA [12] Coded from video of the
child-parent play-session at home (baseline, 7 months mid-
point, 12-month endpoint) and child-learning support as-
sistant play-session in school (baseline, 7 months interim,
12-month endpoint). This measure includes independent
codes of parental communication (synchrony) and child
communication (initiations). This measure proved sensitive
in the original PACT mediation analysis and will be used in
PACT-G to test treatment effect and mediation in home
and education settings.
Secondary outcome
Vineland Adaptive Behaviour Scales Parent and
teacher versions (P/T-VABS) [35]. The VABS includes
domains of communication, daily living skills and social-
isation, and has been used in numerous autism studies. It
will be a measure of functional gains by the child in the
home and education settings.
MacArthur-Bates Communicative Development In-
ventories (Word and Gestures; Sentences and Gram-
mar) [36]; and Receptive and Expressive One-word
Picture Vocabulary Test [37]; and Pre-school Lan-
guage Scale-5 [38] The overall language level measured
by these standardised assessments supplements that of
the measures of autism-specific communication included
in the BOSCC and ADOS.
The Early Sociocognitive Battery of the Very Early
Processing Skills [39, 40] This assesses children’s
sociocognitive skills (social responsiveness, joint atten-
tion and symbolic comprehension).
Repetitive Behaviours Questionnaire [41] A 26-point
parent questionnaire for assessing repetitive behaviours
in children with ASD.
The Developmental Behaviour Checklist-Parent (2nd
Edition; DBC-P) [42] Disruptive/Anti-social and Anx-
iety Subscales A 96-item instrument used for the as-
sessment of behavioural and emotional problems in
young people aged 4–18 years with developmental and
intellectual disabilities. It is completed by a parent or
carer. In PACT-G we will use two subscales: the Dis-
ruptive/Anti-social and the Anxiety Subscale. This
constitutes 36 items.
Strengths and Difficulties Questionnaire (SDQ) –
Parent and Teacher versions A 25-item brief measure
of psychological wellbeing in 2–17 year olds (Goodman,
1997) [43]. In PACT-G, it will be completed by both par-
ents and teachers.
Child Health Utility 9D [44] (CHU9D) A paediatric
measure of health-related quality of life. It consists of nine
items, each responded to with one of five levels (ranging
from no problems to severe problems). The CHU9D is de-
signed to be completed by children aged 7–17 years. Proxy
completion is also possible for younger/developmentally
disabled children. In PACT-G parents will be asked to
complete this questionnaire on behalf of their child.
Warwick and Edinburgh Mental-Wellbeing Scale
[45] Parent-rated wellbeing questionnaire recommended
by UK Department of Health as the preferred measure
of mental wellbeing important to incorporate in studies
of this kind.
Tool to Measure Parental Self-efficacy [46] A 48-item,
self-report measure of parenting competence. It is a
measure of possible change in parent’s confidence in
their ability to make a difference to their child’s develop-
ment. Completed at baseline and endpoint assessments.
Child and Adolescent Service Use Schedule (CA-
SUS) [25] and School Service Use Schedule Developed
to record therapies and service use accessed throughout
participation in the study. Forms were adapted to young
populations with autism in our PACT and PACT 7–11
studies [6].
Working Alliance Inventory – Short Revised (WAI-SR)
[47] A measure of engagement with therapy for parents
and learning support assistants in intervention group
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only. For parents and LSAs, there is a simple rewording
of the client and therapist versions of the WAI-SR,
which has been validated and is now frequently used. This
will be completed at 2 and 5 months into the intervention.
Demographic, clinical and family language information
We will collect relevant demographic and clinical in-
formation and details of home language(s) spoken
with the child.
Procedures
Data collection
Research staff will confirm eligibility and obtain consent.
Baseline assessment will be undertaken prior to treat-
ment assignment. Randomisation will be done through
the King’s Clinical Trials Unit web-based randomisation
service. Allocation will be by stratified block randomisa-
tion, controlling for treatment centre, age strata (under
fifth birthday, fifth birthday and older) and gender. Each
case will be assigned a participant ID number and treat-
ment allocation emailed separately to the treatment
centre therapists.
The primary outcome and putative mechanisms are
coded from videotape, by researchers at the other sites,
trained to high levels of reliability and blinded to inter-
vention allocation. A randomly selected proportion of
assessments will be double rated for reliability. All other
researcher assessments are also blinded; parent and
teacher questionnaires/interview measures non-blinded.
Participant families cannot be blinded to allocation.
All therapy sessions are videotaped. Variability due to
therapist effects will be minimised by frequent clinical
supervision and checks on continuing therapist fidelity
against the treatment manual; randomly selected ses-
sions for each therapist will be formally coded for fidelity
over the course of the study by independent clinicians
using the model successfully used in PACT.
Adverse events are enquired for by researchers at each
contact with the family. Adverse events are also collected
in parallel by trial therapists, as and when a situation
becomes known to them, and documented separately. As
well as recording adverse events in a pre-defined standard
format, we include adverse events relating to child health,
wellbeing and behaviour, significant issues at school, and
family events such as separation or significant parental
ill-health.
Extensive information-sharing and engagement activ-
ities with clinical teams and local mainstream and spe-
cialist schools will be undertaken to promote clinical
referrals and engagement with both home and education
aspects of the intervention. Regular trial newsletters to
participating families, schools and nurseries and clinical
teams, along with voucher payments to schools and nur-
series will act to maintain involvement and adherence.
Families receive an individualised feedback report on the
assessments conducted with their child, copied to school
and clinical teams if desired. A local referring clinician
for each participant will be informed of study progress
and findings, with procedures for clinical support and
aftercare beyond the study should this be necessary.
Data management
All data in the trial will be anonymised. A central master
file will be held by the trial manager at The University of
Manchester. This will contain the key linking anon-
ymised trial name to personal details. The main trial
data will be entered into the web-based data entry ser-
vice of King’s College Clinical Trials Unit, which has a
full audit trail. Appropriate quality control will be car-
ried out during the trial and before the database lock.
Primary analysis of the data will take place by the trial
statisticians and chief investigator. Other members of
the team will also have access to data within a publica-
tion protocol agreement, and will be able to undertake
analysis as appropriate and necessary. This could include
analysis of baseline data prior to primary endpoint analysis,
and of outcome data but only after the primary analyses
are completed. Any arrangements for other researchers in
the general field to have access to the primary data will be
negotiated separately and COREC informed.
Statistical analysis
Sample size calculations
The PACT trial showed an effect of ES 1.22 (0.85, 1.59)
on parental synchrony (DCMA), which mediated 70% of
the ES 0.41 (0.08, 0.74) on child communication, which
in turn mediated 72% of the ES 0.24 (0.59, 0.11) on
symptom outcome (ADOS). The intervention strategies
in the PACT-G trial are specifically targeted to enhance
generalisation of the child communication to increase ef-
fects on primary outcome in home, education and re-
search settings. Therefore, we expect the ES for the
symptom outcome to be substantially above 0.24 and clin-
ically meaningful (see above). Power was calculated using
the sampsi command in Stata for an analysis using ana-
lysis of covariance (ANCOVA) with alpha = .05, with pre
and post measures correlated at .67 (based on PACT trial).
With 110 cases followed up in each group (70/70
pre-school and 40/40 school-age) 80% power is retained
for ES = 0.28 and 90% power for ES = 0.33. Allowing for
10% attrition (compared to 4% in PACT) we propose
to recruit 244 families (~ 82/site − 52 pre + 30
school-age).
Analysis plan
A statistical analysis plan will be written by the trial stat-
isticians (AP and RE) and agreed by the trial principal
investigators before submitting for approval by the Trial
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Steering Committee and Data Monitoring Committee
before any analysis is undertaken. All statistical analyses
will be carried out using the latest version of Stata [48]
or MPlus [49].
In accordance with the Consolidated Standards of
Reporting Trials (CONSORT) Statement for non-
pharmacological interventions, we will report all par-
ticipant flow. Descriptive statistics will summarise
recruitment, drop-out and completeness of interven-
tions. Analysis will be undertaken after all 12-month
outcome measures are completed. The main efficacy
analysis will follow intention-to-treat principles. For
the primary outcome, baseline measurement will be
complete, since required for randomisation. The proposed
ANCOVA will provide estimates under an assumption of
a missing-at-random (MAR) data mechanism. For second-
ary outcome measures the ANCOVA will be estimated
using simultaneous equations for both baseline and
follow-up measurements, including all participants with
any pre- or post-randomisation measure under the MAR
assumption. Where outcomes are unavailable on more
than 10% of participants, a sensitivity analysis will be
undertaken in which outcome scores will be multiply im-
puted using relevant available auxiliary baseline and
follow-up measures and assuming the absence of a treat-
ment effect. There will be no planned interim analysis for
efficacy or futility. Summary statistics of baseline charac-
teristics will be presented by randomised group without
formal statistical tests.
Phase 1 – Efficacy analysis
We will test the primary hypothesis for between-group dif-
ference in the outcome ADOS total score using linear re-
gression, stratified by ADOS module, covarying by baseline
ADOS total score and dummy variables for site, gender
and age group. Standard residual diagnostics will be ap-
plied and skew minimising transformations adopted where
required. An overall effect size will be calculated pooling
stratum specific estimates for strata defined by the ADOS
module, weighted by their precision, using a 95% confi-
dence interval estimated from 5000 bootstrap replicates.
The secondary outcomes will be analysed in a similar
way but without stratification by ADOS module. A for-
est plot of effect sizes for primary and secondary out-
comes will be presented. A test of homogeneity of effect
size for the ADOS and BOSCC will be reported.
The primary paper will report a test of homogeneity
of effect for the primary outcome in pre-school and
school-age children. To be consistent with the treat-
ment main effects analysis, the test of difference in
treatment effect by age group will be based on the
bootstrap p value over 5000 replicates of the pooled
within-ADOS stratum estimate of the treatment differ-
ence. A secondary paper (see phase 3) will report an opti-
mal moderation index [50] including bias correction from
over-fitting to a finite sample.
Phase 2 – Mechanisms’ evaluation
Mediation analysis [15] gave detailed insight into an attenu-
ated generalization in the original PACT trial across change
in person, task and context (as above and Fig. 1). In
the PACT-G trial we enhance generalisation into home by
keeping parental dyadic cues constant, but increasing func-
tionally relevant interaction contexts; and into education by
enhancing relevant communication with education staff
(LSA). The mechanism study will investigate the mediation
process in this model and, through that, illuminate key basic
knowledge about generalisation of acquired skills in autism.
Some of the pathways of interest are illustrated in
Fig. 3. If the efficacy analysis shows significant
between-group differences in the mediators (DCMA
and/or BOSCC at home (path a) and in education
contexts (path c)), then we will use parametric
regression models to:
Fig. 3 Key mediation pathways to be tested in the Paediatric Autism Communication Therapy-Generalised (PACT-G) Trial mechanism study
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1. Test for mediation of the intervention on primary
symptom outcome (ADOS) through DCMA and/or
BOSCC at home (paths a,e,f )
2. Test for mediation of the intervention on primary
symptom outcome through DCMA and/or BOSCC
in the education setting (paths c,d,f )
3. Test for mediation of intervention on DCMA and/
or BOSCC in education setting through DCMA
and/or BOSCC at home (paths a,b,c)
4. Use structural equation modeling to examine
multiple pathways through DCMA and/or BOSCC
at home and in the education setting to primary
symptom outcome (paths a–f )
We will also repeat these four steps using researcher
BOSCC as the outcome variable in place of the ADOS.
Since all the measures are continuous, the indirect ef-
fects are calculated by multiplying relevant pathways
and bootstrapping is used to produce valid standard
errors for the indirect effects. All analyses will adjust for
baseline measures of the mediators (BOSCC/DCMA),
outcome (ADOS) and putative measured confounders.
Mediation analyses are potentially biased by measure-
ment error in mediators and hidden confounding be-
tween mediators and outcomes; we will build on our
previous methodological and applied work in this con-
text to include repeated measurement of mediators and
outcomes to account for classical measurement error
[15] and baseline confounding [51]. We will investigate
the sensitivity of the estimates to these problems and that
of unmeasured confounding using instrumental variable
(IV) methods [52] with baseline covariate by randomization
interactions as potential instruments [52].
Treatment compliance in the education setting is likely
to be more variable than the high levels achieved with par-
ents. We will estimate a complier average causal effect
(CACE) estimate using instrumental variable methods,
considering the extent of education-setting opt-in as
a measure of compliance and randomisation as the
instrumental variable.
Phase 3 – Moderation and subgroups
We will test whether the mediation analysis is consistent
across the two age groups by testing for moderation of paths
a–f by age-group stratifier (including interaction terms or
performing a multiple group analysis in the structural
equation model). We will test ‘moderated mediation’ on our
pathway from intervention to interaction with an unfamiliar
assessor, extending our understanding of generalisation
processes in autism. The heterogeneity of autism is
well-recognised and as such offers numerous potential mod-
erators of treatment effects (e.g. language level, restricted
and repetitive behaviour, functional impairment). We will
examine an extended list of moderators using bias
correction/cross-validation methods to identify robust evi-
dence for moderation and for a moderation index, both on
the overall effect and also along the steps of the mediation
pathway.
Discussion
This trial addresses a number of contemporary challenges
in autism intervention research. Firstly, it addresses the
challenge of implementation of a clinic-based treatment
into the naturalistic community contexts of home and
education. The logic for undertaking this generalised im-
plementation is to address a second key difficulty within
autism development; that is the difficulty that children
with autism have in generalising acquired skills across
context and person. This barrier to generalisation in aut-
ism has been a significant issue limiting the everyday and
functional effectiveness of interventions for child adapta-
tion and development. Thirdly, the study extends the age
of primary intervention into the early school years,
whereas most early psychosocial interventions to date
have been implemented in the pre-school period.
The study will take a rigorous approach to outcome
assessment with objectively measured autism symptoms
(i.e. the defining characteristics of the disorder) as the
primary outcome. It will use new techniques in objective
measurement of autism symptomatology in naturalistic
contexts to test the differential effect of intervention in
home and school, and any additive effects that may occur.
Secondary outcomes will test a range of parent- and
teacher- rated outcomes relating to development, behav-
iour, adaptation, parental wellbeing and self-efficacy and
family quality of life. These are designed to capture the
effect of intervention in the widest possible way within the
child’s development and social and family context.
The trial and the mechanism analysis will allow the
testing of how effects in different naturalistic contexts
relate together and contribute to overall developmental
outcomes. This will result in novel and important infor-
mation relating to the issue of the generalisation of
acquired skills in autism and the impact of this on devel-
opment and susceptibility to treatment.
Implementation of a video-aided intervention of this
kind in the home and school context will be challenging
since many aspects of the environment in both these
contexts may interfere with the focus necessary for
therapeutic work. These challenges have to be balanced
against the potential advantages of naturalistic context
intervention. We have built in operational features to try
and mitigate these challenges and have also included
within the protocol a regular structured collaborative
conversation between parents and teachers with the aim
of enhancing the integration of the parallel home and
education treatment programmes. In doing this work
the trial will address core current NHS priorities in child
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development and mental health, for instance the em-
phasis on evaluation of school-based intervention in re-
cent health policy. The three-site design of the study, in
major urban/semi-urban geographically disparate centres
will, from our previous work, provide a useful range of
geographic coverage and social demographic representa-
tion for the study design. The trial’s focus on autism
symptoms as the primary outcome is consistent with
our previous work, addressing the core defining charac-
teristics of the disorder. We will utilise new leading
measurement techniques in autism symptom outcome
estimation. The data-rich, repeated-measures design will
give enhanced power to account for the inevitable meas-
urement error in behavioural studies of this kind and
allow sophisticated mediation/mechanism modelling of
the findings. The outcomes of the trial will add important
information to our knowledge about effective interven-
tions for autism development (Additional file 1).
Trial status
Protocol: Version 6. 12 March 2018.
Recruitment began on 18 January 2017 and completed
on 30th April 2018.
Monitoring
Sponsor and monitor
Manchester University NHS Foundation Trust, Dr. Lynne
Webster, Central Research Office, Nowgen Building,
Grafton Street M13 9WL. Telephone: 01612764125.
Trial Steering Committee
Composition: Professor Stuart Logan, University of Bristol
(Chair); Professor Anne O’Hare, University of Edinburgh;
Professor Liz Pellicano, Macquarie University, Sydney
(resigned); Dr Emily Jones, Birkbeck College London; Ms
Louisa Harrison (parent representative); Ms Kellie Bell
(parent representative); Professor Jonathan Green, University
of Manchester (CI). The TSC is independent of sponsor and
funder and declares no competing interests.
Data Monitoring and Ethics Committee
Composition: Professor Paul Ramchandani, University of
Cambridge (chair); Professor Amanda Farrin, University
of Leeds; Professor Jacqueline Barnes, Birkbeck College,
London; Professor Andrew Pickles (PI statistician), King’s
College London. The DMEC is independent of sponsor
and funder and declares no competing interests. Further
details of the DMEC charter are available from Professor
Andrew Pickles, King’s College London. There is no
planned formal interim analysis.
Project Management Group
A Project Management Group will be chaired by CI
Professor Green and consist of the principal
investigators and senior researchers on the trial, the trial
manager and other invited members as necessary. It will
meet at least quarterly, with additional tele or
video-conferencing as necessary.
Harms
We will actively collect information at each assessment
point of the trial about adverse events. In addition to
recording adverse events in the standard way, we will
include events particularly relevant to this trial, such as sig-
nificant changes in family or school situation. There are
standard operating procedures for reporting serious adverse
events to the Project Management Group, TSC, DMEC,
sponsor and funder, for consideration of appropriate action.
Auditing
Trial conduct is monitored by regular auditing visits from
the sponsor, annual reports to the NHS Research Ethics
Committee (REC), bi-annual reports to the funder and regu-
lar Trial Steering Committee meetings. Protocol amend-
ments will be formally recorded and communicated to the
Project Management Group, REC, funder (NIHR EME),
DMEC, TSC and reported in the trial registration site.
Dissemination
The results of the research will be targeted for publication
in peer-reviewed journals of general and special interest.
There will also be a general dissemination programme for
families including participants co-ordinated through our
collaborators in the National Autistic Society. Individual
feedback for participants will be through the regular trial
newsletter. Authorship on dissemination papers will fol-
low ICMJE guidelines and journal requirements. There
will be no use of professional writers.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (PDF 107 kb)
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